A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Phase 2 Recruiting 160 enrolled Incyte Corporation ENGOT Foundation · collab GOG Foundation · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Timeline

Start: 2025-11-12
Primary completion: 2027-04-27
Completion: 2027-10-24

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCB123667	Unknown	—	Oral

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Summary

Timeline

Drugs

Indications